The US Food and Drug Administration (FDA) has approved Merz North America’s supplemental biologics license application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, otherwise known as excessive drooling. This makes Xeomin the […]
Boehringer Ingelheim has added a new filling line to its Oasis facility in Shanghai, China in order to expand and consolidate its contract drug manufacturing capabilities.The expansion means the company’s contract manufacturing business Boehringer Ingelheim […]
SMi Group reports: Exclusive interviews with Toni Mathieson – Niemann-Pick UK and Nicolas Sireau – AKU Society in the run up to theOrphan Drugs and Rare Diseases Conference taking place on the 17 – 18 […]
SMi Group are delighted to welcome expertise from a senior panel of big pharma and cold chain organisations and regulatory bodies, at the 13th annual industry leading conference on Cold Chain Distribution 2018, taking place […]
SMi Group are delighted to welcome the expertise from a senior panel of big pharma and ophthalmic organisations, as well as regulatory bodies, at the 2nd annual Ophthalmic Drugs 2018 conference, taking place in November […]